Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.3.0.814
Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Segment Reporting Information [Line Items]          
Revenue from services $ 103,919 $ 2,482 $ 107,929 $ 6,606  
Product revenues 20,765 17,291 59,066 58,510  
Other revenue, principally transfer of intellectual property 18,350 0 48,552 476  
Operating (loss) income (8,223) (48,201) (90,547) (113,361)  
Depreciation and amortization 12,399 3,768 20,073 11,269  
Net loss from investment in investees (3,502) (60) (6,067) (2,486)  
Total revenues 143,034 19,773 215,547 65,592  
Assets 3,015,853   3,015,853   $ 1,267,664 [1]
Goodwill 761,234   761,234   224,292 [1]
United States          
Segment Reporting Information [Line Items]          
Total revenues 104,358 2,482 109,359 7,082  
Ireland          
Segment Reporting Information [Line Items]          
Total revenues 22,308 0 53,807 0  
Chile          
Segment Reporting Information [Line Items]          
Total revenues 7,779 7,622 22,929 22,758  
Spain          
Segment Reporting Information [Line Items]          
Total revenues 3,447 4,414 12,303 16,230  
Israel          
Segment Reporting Information [Line Items]          
Total revenues 4,154 3,710 14,309 14,563  
Mexico          
Segment Reporting Information [Line Items]          
Total revenues 988 1,528 2,840 4,905  
Other          
Segment Reporting Information [Line Items]          
Total revenues 0 17 0 54  
Corporate          
Segment Reporting Information [Line Items]          
Revenue from services 20 60 140 180  
Other revenue, principally transfer of intellectual property 0 0 0 0  
Operating (loss) income (11,562) (6,384) (34,444) (19,557)  
Depreciation and amortization 22 31 68 72  
Net loss from investment in investees 0 0 0 0  
Assets 465,626   465,626   95,094
Goodwill 0   0   0
Segment Reconciling Items          
Segment Reporting Information [Line Items]          
Operating (loss) income 0 (599) (1,281) (1,762)  
Pharmaceuticals | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue from services 160 0 192 0  
Product revenues 20,765 17,291 59,066 58,510  
Other revenue, principally transfer of intellectual property 18,350 0 48,552 285  
Operating (loss) income 5,300 (34,480) (36,861) (71,421)  
Depreciation and amortization 2,775 2,020 6,902 6,061  
Net loss from investment in investees (3,502) (60) (6,067) (2,486)  
Assets 1,262,373   1,262,373   1,064,498
Goodwill 237,518   237,518   173,327
Diagnostics | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue from services 103,739 2,422 107,597 6,426  
Other revenue, principally transfer of intellectual property 0 0 0 191  
Operating (loss) income (1,961) (6,738) (17,961) (20,621)  
Depreciation and amortization 9,602 1,717 13,103 5,136  
Net loss from investment in investees 0 $ 0 0 $ 0  
Assets 1,287,854   1,287,854   108,072
Goodwill $ 523,716   $ 523,716   $ 50,965
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 5. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.